# Immunodynamic changes in a mouse model of malignant pleural effusion

**Authors:** Xiao-Lei Wei, Xu Guo, Chuang-Xin Zhang, Qi Wang, Xiao-Fan Liu, Ming-Ming Shao, Huan-Zhong Shi, Kan Zhai

PMC · DOI: 10.1186/s42826-026-00268-8 · Laboratory Animal Research · 2026-03-24

## TL;DR

This study tracks immune changes in mice with a cancer-related fluid buildup, showing how the immune system shifts from active to suppressed as the disease progresses.

## Contribution

The study provides a detailed timeline of immune cell dynamics during MPE progression in a mouse model, identifying distinct early and advanced immunological stages.

## Key findings

- Early MPE is marked by increased B cells, T cells, and natural killer cells but not macrophages or neutrophils.
- Advanced MPE features immunosuppressive traits like reduced T cell activity and increased PD-1 and PD-L1 expression.
- M2 macrophages and Th1 cells show functional decline in advanced MPE, suggesting a shift toward immune tolerance.

## Abstract

Malignant pleural effusion (MPE), a common complication of advanced cancers, is associated with poor prognosis and reduced quality of life. Although host–tumor interactions are known to drive MPE development, the associated immune dynamics during disease progression remain unclear. Using a Lewis lung carcinoma-induced MPE model in C57BL/6JNidfc mice, we systematically evaluated general parameters and immune cell changes at two-day intervals throughout disease progression.

The day of Lewis lung carcinoma cell injection into the pleural space was designated as day 0. By day 10 post-injection (p.i.), MPE-bearing mice exhibited ~ 10% body weight loss, marking the experimental endpoint. Pleural tumor mass and pleural effusion volume were minimal up to day 4 p.i. but increased sharply from day 6 onward. CD45⁺ immune cell counts rose over time, and days 6, 8, and 10 p.i. marked key stages of MPE progression. On day 6, B cells, T cells, and natural killer cells, but not macrophages and neutrophils, increased significantly compared to earlier timepoints. By day 8, all immune cell subsets except T cells exceeded day 6 levels, and at day 10, natural killer cell numbers declined while others continued to increase. Besides, the numbers of CD8⁺ T cells, Th1 cells, regulatory T cells, and M2 macrophages progressively increased from day 6 to 10. Based on these data, days 6 and 10 were defined as early and advanced MPE stages, respectively, with distinct immune phenotypes. In advanced MPE, CD8⁺ T cells displayed reduced IFN-γ, TNF-α, Granzyme B, Perforin, FasL, and Ki-67, but upregulated PD-1 and CTLA-4 relative to early stage. Similarly, Th1 cells showed decreased IFN-γ, TNF-α, and IL-2 production along with reduced Ki-67 expression. Advanced-stage M2 macrophages exhibited lower MHC-II levels and impaired phagocytosis, but higher PD-L1 and IL-10 production, while neutrophils showed reduced TNF-α release and phagocytic activity.

Our findings characterize the temporal immune dynamics associated with MPE progression in a mouse model, revealing a transition from an early immunostimulatory state to a late immunosuppressive state. This study enhances our understanding of MPE immunopathogenesis and provides a foundation for developing precise, stage-specific therapeutic strategies.

The online version contains supplementary material available at 10.1186/s42826-026-00268-8.

## Linked entities

- **Proteins:** IFNG (interferon gamma), TNF (tumor necrosis factor), PRF1 (perforin 1), FASLG (Fas ligand), Mki67 (antigen identified by monoclonal antibody Ki 67), PDCD1 (programmed cell death 1), CTLA4 (cytotoxic T-lymphocyte associated protein 4), H2 (histocompatibility-2, MHC), CD274 (CD274 molecule), IL10 (interleukin 10), IL2 (interleukin 2)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Diseases:** malignant pleural effusion (MESH:D016066)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13011476/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13011476/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC13011476/full.md

---
Source: https://tomesphere.com/paper/PMC13011476